Lowest Price Guaranteed From USD 799
Published
April 2014
Slides
Not Available
View Count
4810
Available on request
With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. It is also known as keratoconjunctivitis sicca. To date, there is no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. A greater risk of acquiring dry eye is also experienced by females, with postmenopausal women being particularly at risk.
In the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in the US. For patients, the average annual direct cost ranges from USD 678 for patients with mild dry eye to USD 1,267 for severe cases. If pharmaceuticals and punctual plugs are included, the cost for these patients rises to USD 2,959 annually. Furthermore, dry eye increases lost productivity through both absenteeism and decreased presenteeism, with the former ranging from 8.4 to 14.2 days per year depending on severity and the latter ranging from 91 to 128.2 days per year depending on severity.
The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of dry eye. We have identified a number of such trials which are taking place across multiple geographies. For each specific trial, we have provided the following information:
The above information has also been presented in the form of a dashboard to provide a high level quick overview of the ongoing activity in this space.
Section 1: Market Overview
Section 2: Dashboard: Pipeline Analysis
Section 3: Molecules in Clinical Development: Trial Details
Section 4: Molecules in Preclinical Development: Trial Details
Section 5: Excluded Drugs
Section 6: Inclusion / Exclusion Criteria
Figure 1: Molecules in Clinical Development: Distribution by Companies
Figure 2: Molecules in Clinical Development: Distribution by Highest Phase of Development
Figure 3: Molecules in Clinical Development: Distribution by Treatment Target
Figure 4: Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
Figure 5: Clinical Trials: Distribution by Trial Status
Figure 6: Clinical Trials: Distribution by Trial Phase
Figure 7: Clinical Trials: Distribution by Route of Administration
Figure 8: Clinical Trials: Distribution by Sponsor Type
Figure 9: Clinical Trials: Distribution by Region
Figure 10A: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 1
Figure 10B: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 2
Figure 10C: Clinical Trials: Distribution by Molecules and Regions (Matrix View) – Set 3
Figure 11: Clinical Trials: Distribution by G7 Countries
Figure 12: Clinical Trials: Distribution by EU5 Countries
Table 1: Molecules in Clinical Development: Pipeline Details
Table 2: Molecules in Preclinical Development: Pipeline Details
The following companies and organisations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES